ROIV data and LISRAYA launch cited as autoimmune momentum drivers
TradingView News cites PHocus phase IIb data in PH-ILD showing record efficacy, prompting rapid phase III enrollment. It also says LISRAYA launched for dermatomyositis with strong clinical and steroid-sparing benefits, while an FcRn pipeline advances across autoimmune diseases.
PHocus phase IIb data in PH-ILD showed record efficacy, prompting rapid phase III enrollment and expanding potential future indications. LISRAYA launched for dermatomyositis with strong clinical and steroid-sparing benefits, while the FcRn pipeline is advancing across multiple autoimmune diseases, with key…